Matt Henriksen

But that manufacturing component and that capacity...

How much of a difference is the manufacturing process for the 15-day versus the 10-day?

Is that part of the transition as well?

Or is it something where the 10-day is now approved for 15-day and it's the same manufacturing process?

Yeah.

And then it's not just the G7 15-day wear that you're launching.

You're also launching the Stello device.

How is the Stello device different from these G7 sensor based off of technology or what customers it's targeting?

Oh, that's interesting because, you know, you talked about the out-of-pocket pay.

I'm like, oh, so reimbursement will come up for Stello eventually.

But it sounds like if you would do the reimbursement pathway, it would just be expanding the G7 reimbursement pathway for those type 2 non-insulin patients?

Or is there still a path for reimbursement for those Stello devices?

Yeah.

And that's a really interesting thing about this spectrum of patients because you got the insulin intensive and they need to measure, they need that

measurement every five minutes to make sure that whether or not they need to incorporate more insulin or they need to get a drink of orange juice.

And then the other end of the spectrum, which is the prediabetes, and they don't need it every day.

Because then it comes with my, you know, I was doing my math and you talked about stello sales being 130 million in 2025.

I think my rough math was about 35 million in 2024.

You do $50 per sensor.

You do 500,000 users since the launch.